JUSCO & YANFENG Projects
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Download Article (PDF)
International Forum on Management, Education and Information Technology Application (IFMEITA 2016) Traffic Simulation of Hongqi Elevated Road in Yantai Feng Zhua, Chengxuan Caob State Key Laboratory of Rail Traffic Control and Safety Beijing Jiaotong University, Beijing 100044, China. a15125815@ bjtu.edu.cn, [email protected] Keywords: Traffic simulation, Hongqi Elevated Road, VISSIM. Abstract. With the increasing number of vehicles in Yantai, the downtown traffic volume is increasing. Hongqi Road, the main road in Yantai exists the traffic congestion problems. Yantai Planning Bureau proposed to construct for viaduct this road. This design is mainly based on the planning and design of the elevated road in Yantai Hongqi Road (Hongqi Road intersection-Shanhai Road intersection). We used the VISSIM micro simulation system to carry out the simulation of the elevated road in Hongqi Road, and the stops and queue length are the evaluation indices for quantitative evaluation. Then through the evaluation indices and specific data obtained by simulation, we analyze the selection of the scheme and draw the final plan of the construction of the elevated road, which was provide a good reference for the planning and construction of Hongqi elevated road. Introduction The emergence of the viaduct is a very important detail in the course of the evolution of the city. It reflects the city's increasingly crowded trends and the city's displacement in space form (from a horizontal plane to a vertical section) [1]. After Hongqi elevated road built, this east-west freeway will remain basically smooth all the way, this will further widen the urban framework, improve the speed of vehicle driving and the traffic capacity of Hongqi road, guarantee the none-congestion of the backbone, increase the efficiency of the green time and reduce the traffic delay. -
Table of Codes for Each Court of Each Level
Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115 -
Microrna-1294 Targets HOXA9 and Has a Tumor Suppressive Role in Osteosarcoma
European Review for Medical and Pharmacological Sciences 2018; 22: 8582-8588 MicroRNA-1294 targets HOXA9 and has a tumor suppressive role in osteosarcoma Z.-F. ZHANG1, G.-R. LI2, C.-N. CAO3, Q. XU1, G.-D. WANG1, X.-F. JIANG1 1Department of Joint Surgery, Yantai Yuhuangding Hospital, Yantai, Zhifu District, Yantai, Shandong, P. R. China 2Department of Spinal Surgery, Yantai Yuhuangding Hospital, Yantai, Zhifu District, Yantai, Shandong, P. R. China 3Department of Hyperbaric Oxygen Therapy, Yantai Yuhuangding Hospital, Yantai, Zhifu District, Yantai, Shandong, P. R. China Zuofu Zhang and Guangrun Li contributed equally to this work Abstract. – OBJECTIVE: MicroRNA-1294 cer type worldwide1,2. OS has a high potential for (miR-1294) was reported to act as a tumor sup- metastasis that results in the unsatisfactory OS pressor in several cancers. However, the biolog- prognosis despite the great achievements in the ical function of miR-1294 in osteosarcoma (OS) treatment measures in recent decades3-5. Hence, has not been investigated. We, therefore, inves- tigated the clinical significance and underlying there is an urgent requirement to deeply investi- mechanisms of miR-1294 in OS. gate the abnormally expressed molecules related PATIENTS AND METHODS: Quantitative Re- to the metastasis of OS to provide novel sugge- al-Time-Polymerase Chain Reaction (qRT-PCR) stions to develop anti-cancer therapeutic strate- was conducted to detect the levels of miR-1294. gies. Extensive studies have revealed the initia- Targets of miR-1294 were validated by luciferase tion and progression of OS is associated with the reporter assay and Western blot. In vitro functional abnormal expression of tumor suppressor genes assays were performed to investigate the effects 5,6 of miR-217 on cell proliferation and invasion. -
Yantai NEW City Guide
YANTAI CITY GUIDE INTRODUCTION Yantai is a charming coastal city located in the northeastern Shandong Province. It offers a picturesque and romantic seascape, best enjoyed with a glass of the locally produced, internationally recognized ‘Changyu’ wine. The wine culture, delicious seafood and colonial-era western architecture has made Yantai an increasingly popular tourist destination. Penglai, just 65km away, is known as a fairyland on earth, because of its majestic scenery and links with a number of Chinese legends. Yantai's population as of 2018 is just over 7 million. The average high temperature in the summer is 30°C, while spring and autumn are quite mild. Winters can be quite cold, dipping below 0°C. The total GDP of Yantai surpassed 110 billion USD in 2018. 7 million 30°C -4°C GDP $110bn 1 CONTENTS Culture History & Natural Wonders Cuisine Industry Maps Popular Attractions Transport Housing Schools Doctors Shopping Nightlife Emergency Contacts 2 CULTURE Changyu wine, produced in Yantai, has thrust Yantai onto the world wine stage. Yantai has become as beloved a name to lovers of Chinese wines as is Bordeaux to lovers of French wines. Since Yantai is located very close to the sea, Yantai’s culture is also deeply tied to the coast. Yantai Hill, in the north of the city proper and surrounded by sea on three sides, houses a large collection of colonial-era Western architecture, including a famous lighthouse you can climb. The buildings have been well preserved, and the park is renowned as a living museum of Western treaty port architecture. 3 HISTORY & NATURAL WONDERS Penglai has long been a popular tourist destination. -
Country Advice China China – CHN36486 – Shandong Province – Yantai – Hebei North University – Detention Centres 22 April 2010
Country Advice China China – CHN36486 – Shandong Province – Yantai – Hebei North University – Detention centres 22 April 2010 1. Is there a Hebei North University at No. 14, Chang Qing Rd., Zhangjiakou city, Hebei Province? There is a campus of Hebei North University1 (河北北方学院) at No. 14 Changqing Rd, Zhangjiakou City, Hebei. The Hebei North University website is mainly in Chinese http://www.hebeinu.edu.cn/, with a small English section. Google Maps also shows this campus, as the site Hebei North University School of Medicine (of 河北北方学院医学院) and Hebei North University College of Medical Technology (河北北方学院医学技术学院).2 The main address on the Chinese version of the website is 张家口市高新区钻石南路11号. (11 Zuanshi Nanlu (11 Diamond Rd South), Gaoxin (ward), Zhangjiakou City). A map of the University and surrounds is at Attachment 9. Information on the University website3 shows that there are other campuses including one at 河北省张家口市长青路14号邮编 (14 Changqing Rd, Zhangjiakou City, Hebei province).4 (The website lists four campuses: The West campus, the East campus, the South campus and the Changqing Rd campus.)5 A Chinese studyguide gives an overview of the university, stating: Hebei North University is a provincial-administrated multi-faculty university, which can grant Batchlor (sic) Academic Degree and Master Academic Degree. The University was founded in May 2003, approved by Ministry of Education and combined from former three provincial-administrated institutions of higher learning in Zhangjiakou: Zhang jiakou Medical College (ZJKMC), Zhangjiakou Teacher’s College (ZJKTC), Zhangjiakou Advanced Postsecondary Agronomy School (ZJKAPAS). [All the three colleges have long history of school-running and contribute greatly to talents education, knowledge creation and social development.] [It is the] only multi-faculty university in the north of Hebei Province. -
Addition of Clopidogrel to Aspirin in 45 852 Patients with Acute Myocardial Infarction: Randomised Placebo-Controlled Trial
Articles Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group* Summary Background Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and Lancet 2005; 366: 1607–21 morbidity remain high. The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary See Comment page 1587 syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear. *Collaborators and participating hospitals listed at end of paper Methods 45 852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly Correspondence to: allocated clopidogrel 75 mg daily (n=22 961) or matching placebo (n=22 891) in addition to aspirin 162 mg daily. Dr Zhengming Chen, Clinical Trial 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to Service Unit and Epidemiological Studies Unit (CTSU), Richard Doll continue until discharge or up to 4 weeks in hospital (mean 15 days in survivors) and 93% of patients completed Building, Old Road Campus, it. The two prespecified co-primary outcomes were: (1) the composite of death, reinfarction, or stroke; and Oxford OX3 7LF, UK (2) death from any cause during the scheduled treatment period. Comparisons were by intention to treat, and [email protected] used the log-rank method. This trial is registered with ClinicalTrials.gov, number NCT00222573. or Dr Lixin Jiang, Fuwai Hospital, Findings Allocation to clopidogrel produced a highly significant 9% (95% CI 3–14) proportional reduction in death, Beijing 100037, P R China [email protected] reinfarction, or stroke (2121 [9·2%] clopidogrel vs 2310 [10·1%] placebo; p=0·002), corresponding to nine (SE 3) fewer events per 1000 patients treated for about 2 weeks. -
Tax Analysis
Tax Issue P243/2016 – 8 August 2016 Tax Analysis Authors: Chinese court rules Hong Kong offshore merger by Ryan Chang Partner Tel: +852 2852 6768 absorption does not Email: [email protected] qualify for special Shanghai Kevin Zhu Director reorganization relief Tel: +86 21 6141 1262 Email: [email protected] A Chinese court located in Zhifu District, Yantai City in Shandong Province issued a decision in December 2015,1 in which it Moya Wu concluded that the merger of two Italian companies by an Manager upstream absorption (that resulted in a change of the Tel: +86 21 2316 6376 shareholders of a Chinese company) does not qualify for special Email: [email protected] reorganization treatment in China and, hence, the tax authorities' decision to tax the deemed capital gains derived from the share transfer is justified. Under China’s merger and acquisition tax rules (as set out in Circular 59), a reorganization can be considered either an ordinary reorganization or a special reorganization. An ordinary reorganization is taxed under the normal enterprise income tax rules governing the transfer of assets, with any taxable gain or loss recognized at the time of the transaction. By contrast, a special reorganization is a tax-free transaction under which recognition for tax purposes of the gain or loss on the transfer of shares or assets is deferred, provided certain conditions are satisfied. Special rules apply to cross-border reorganizations. Facts of the case The case before the Zhifu court involved a wholly owned Italian subsidiary, Illva Saronno Investment S.r.l. ("Italian Sub"), that was merged into its immediate parent company, Illva Saronno Holding S.p.A. -
The Case and Treatment of Prominent Human Rights Lawyer Gao Zhisheng Hearing Congressional-Executive Commission on China
THE CASE AND TREATMENT OF PROMINENT HUMAN RIGHTS LAWYER GAO ZHISHENG HEARING BEFORE THE CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA ONE HUNDRED TWELFTH CONGRESS SECOND SESSION FEBRUARY 14, 2012 Printed for the use of the Congressional-Executive Commission on China ( Available via the World Wide Web: http://www.cecc.gov U.S. GOVERNMENT PRINTING OFFICE 74–543 PDF WASHINGTON : 2012 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA LEGISLATIVE BRANCH COMMISSIONERS House Senate CHRISTOPHER H. SMITH, New Jersey, SHERROD BROWN, Ohio, Cochairman Chairman MAX BAUCUS, Montana FRANK WOLF, Virginia CARL LEVIN, Michigan DONALD A. MANZULLO, Illinois DIANNE FEINSTEIN, California EDWARD R. ROYCE, California JEFF MERKLEY, Oregon TIM WALZ, Minnesota SUSAN COLLINS, Maine MARCY KAPTUR, Ohio JAMES RISCH, Idaho MICHAEL HONDA, California EXECUTIVE BRANCH COMMISSIONERS SETH D. HARRIS, Department of Labor MARIA OTERO, Department of State FRANCISCO J. SA´ NCHEZ, Department of Commerce KURT M. CAMPBELL, Department of State NISHA DESAI BISWAL, U.S. Agency for International Development PAUL B. PROTIC, Staff Director LAWRENCE T. LIU, Deputy Staff Director (II) CO N T E N T S Page Opening statement of Hon. Chris Smith, a U.S. Representative from New Jersey; Chairman, Congressional-Executive Commission on China ................ 1 Brown, Hon. Sherrod, a U.S. Senator from Ohio; Cochairman, Congressional- Executive Commission on China ........................................................................ 4 Wolf, Hon. Frank, a U.S. Representative from Virginia; Member, Congres- sional-Executive Commission on China ............................................................ -
Analysis of Spatial-Temporal Distribution of Notifiable Respiratory
Li et al. BMC Public Health (2021) 21:1597 https://doi.org/10.1186/s12889-021-11627-6 RESEARCH ARTICLE Open Access Analysis of spatial-temporal distribution of notifiable respiratory infectious diseases in Shandong Province, China during 2005– 2014 Xiaomei Li1†, Dongzhen Chen1,2†, Yan Zhang3†, Xiaojia Xue4, Shengyang Zhang5, Meng Chen6, Xuena Liu1* and Guoyong Ding1* Abstract Background: Little comprehensive information on overall epidemic trend of notifiable respiratory infectious diseases is available in Shandong Province, China. This study aimed to determine the spatiotemporal distribution and epidemic characteristics of notifiable respiratory infectious diseases. Methods: Time series was firstly performed to describe the temporal distribution feature of notifiable respiratory infectious diseases during 2005–2014 in Shandong Province. GIS Natural Breaks (Jenks) was applied to divide the average annual incidence of notifiable respiratory infectious diseases into five grades. Spatial empirical Bayesian smoothed risk maps and excess risk maps were further used to investigate spatial patterns of notifiable respiratory infectious diseases. Global and local Moran’s I statistics were used to measure the spatial autocorrelation. Spatial- temporal scanning was used to detect spatiotemporal clusters and identify high-risk locations. Results: A total of 537,506 cases of notifiable respiratory infectious diseases were reported in Shandong Province during 2005–2014. The morbidity of notifiable respiratory infectious diseases had obvious seasonality with high morbidity in winter and spring. Local Moran’s I analysis showed that there were 5, 23, 24, 4, 20, 8, 14, 10 and 7 high-risk counties determined for influenza A (H1N1), measles, tuberculosis, meningococcal meningitis, pertussis, scarlet fever, influenza, mumps and rubella, respectively. -
CHINA VANKE CO., LTD.* 萬科企業股份有限公司 (A Joint Stock Company Incorporated in the People’S Republic of China with Limited Liability) (Stock Code: 2202)
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. CHINA VANKE CO., LTD.* 萬科企業股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2202) 2019 ANNUAL RESULTS ANNOUNCEMENT The board of directors (the “Board”) of China Vanke Co., Ltd.* (the “Company”) is pleased to announce the audited results of the Company and its subsidiaries for the year ended 31 December 2019. This announcement, containing the full text of the 2019 Annual Report of the Company, complies with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in relation to information to accompany preliminary announcement of annual results. Printed version of the Company’s 2019 Annual Report will be delivered to the H-Share Holders of the Company and available for viewing on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and of the Company (www.vanke.com) in April 2020. Both the Chinese and English versions of this results announcement are available on the websites of the Company (www.vanke.com) and The Stock Exchange of Hong Kong Limited (www.hkexnews.hk). In the event of any discrepancies in interpretations between the English version and Chinese version, the Chinese version shall prevail, except for the financial report prepared in accordance with International Financial Reporting Standards, of which the English version shall prevail. -
Levi Strauss & Co. Factory List
Levi Strauss & Co. Factory List Published : March 2016 Country Factory name Alternative factory name Address City State/Province Argentina Accecuer SA Juan Zanella 4656 Caseros Buenos Aires Avanti S.A. Coronel Suarez 1544 Olavarría Buenos Aires Best Sox S.A. Charlone 1446 Capital Federal Buenos Aires Buffalo S.R.L. Valentín Vergara 4633 Florida Oeste Buenos Aires Carlos Kot San Carlos 1047 Wilde Buenos Aires Ciudad Autónoma de Buenos CBTex S.R.L. - Sew Av. de los Constituyentes 5938 Buenos Aires Aires Estex Argentina S.R.L. Superi, 3530 Caba Buenos Aires Frey S.A. Frey Lebensohn 311 Paso del Rey Buenos Aires Gitti SRL Italia 4043 Mar del Plata Buenos Aires Industrias Seatle S.A. Bermudez 2830 CABA Buenos Aires Khamsin S.A. Florentino Ameghino, 1280 Vicente Lopez Buenos Aires Manufactura Arrecifes S.A. Ruta Nacional 8, Kilometro 178 Arrecifes Buenos Aires Materia Prima S.A. - Planta 2 Acasusso, 5170 Munro Buenos Aires Procesadora Serviconf SRL Gobernardor Ramon Castro 4765 Vicente Lopez Buenos Aires Procesadora Virasoro S.A. Boulevard Drago 798 Pergamino Buenos Aires Procesos y Diseños Virasoro S.A. Avenida Ovidio Lagos, 4650 Rosario Santa Fé Provira S.A. Avenida Bucar, 1018 Pergamino Buenos Aires Spring S.R.L. Darwin, 173 Capital Federal Buenos Aires Sweaters Romano SRL Av. Republica 877 Ciudadela Buenos Aires Top San Juan S.A. Calle General Acha 1122 San Juan San Juan Tricofix S.R.L. Miranda, 5475 Capital Federal Buenos Aires Underwear M&S, S.R.L Levalle 449 Avellaneda Buenos Aires Vira Offis S.A. Virasoro, 3570 Rosario Santa Fé Wittery S.A. -
2000.2.2. L 26/26 Az Európai Közösségek
03/28. kötet HU Az Európai Unió Hivatalos Lapja 205 32000D0086 L 26/26 AZ EURÓPAI KÖZÖSSÉGEK HIVATALOS LAPJA 2000.2.2. A BIZOTTSÁG HATÁROZATA (1999. december 21.) a Kínából származó halászati termékek behozatalára vonatkozó különleges feltételek megállapítá- sáról és a 97/368/EK határozat hatályon kívül helyezéséről (az értesítés a C(1999) 4761. számú dokumentummal történt) (EGT vonatkozású szöveg) (2000/86/EK) AZ EURÓPAI KÖZÖSSÉGEK BIZOTTSÁGA, (7) A CIQ SA hivatalos biztosítékokat nyújtott a 91/493/EGK irányelv mellékletének V. fejezetében tekintettel az Európai Közösséget létrehozó szerződésre, megállapított szabályok betartásáról, valamint az említett tekintettel a legutóbb a 97/79/EK tanácsi irányelvvel (1) módosí- irányelvben megállapítottakkal egyenértékű, a származási tott, a halászati termékek előállítására és forgalomba hozatalára létesítmények, feldolgozóhajók, hűtőházak, illetve vonatkozó egészségügyi feltételek megállapításáról szóló, 1991. fagyasztóhajók engedélyezésére, illetve nyilvántartásba július 22-i 91/493/EGK tanácsi irányelvre (2) és különösen vételére vonatkozó követelmények teljesítéséről. annak 11. cikkére, (8) Az ellenőrző látogatás eredményeire tekintettel hatályon mivel: kívül kell helyezni a legutóbb a 98/321/EK bizottsági határozattal (4) módosított, a Kínából származó egyes (1) A Bizottság egy szakértői csoportja ellenőrző látogatást halászati termékekre vonatkozó bizonyos védőintézkedé- tett Kínában a halászati termékek előállítása, tárolása és sekről szóló, 1997. június 11-i 97/368/EK bizottsági Közösségbe